Thomas J. Schall

31.8k total citations · 14 hit papers
185 papers, 25.8k citations indexed

About

Thomas J. Schall is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Thomas J. Schall has authored 185 papers receiving a total of 25.8k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Immunology, 93 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Thomas J. Schall's work include Chemokine receptors and signaling (79 papers), T-cell and B-cell Immunology (33 papers) and Immunotherapy and Immune Responses (30 papers). Thomas J. Schall is often cited by papers focused on Chemokine receptors and signaling (79 papers), T-cell and B-cell Immunology (33 papers) and Immunotherapy and Immune Responses (30 papers). Thomas J. Schall collaborates with scholars based in United States, United Kingdom and Germany. Thomas J. Schall's co-authors include Kevin B. Bacon, David V. Goeddel, Brett A. Premack, Albert Zlotnik, Karen Toy, Daniel J. Dairaghi, Dan R. Littman, Mark E.T. Penfold, Pirow Bekker and J. Fernando Bazán and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Thomas J. Schall

182 papers receiving 25.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of a major co-receptor for primary isolates of HIV-1

1996 3.0k citations Thomas J. Schall et al. profile →
A new class of membrane-bound chemokine with a CX3C motif

1997 1.6k citations Thomas J. Schall et al. profile →
Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

1990 1.2k citations Thomas J. Schall et al. profile →
Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion

1997 1.2k citations Thomas J. Schall et al. profile →
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

2006 1.0k citations Yu Wang, Zhenhua Miao et al. The Journal of Experimental Medicine profile →
Molecular cloning and expression of a receptor for human tumor necrosis factor

1990 852 citations Thomas J. Schall et al. profile →
Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor

1993 643 citations Thomas J. Schall et al. profile →
Biology of the rantes/sis cytokine family

1991 585 citations Thomas J. Schall profile →
Chemokines, leukocyte trafficking, and inflammation

1994 564 citations Thomas J. Schall et al. profile →
Avacopan for the Treatment of ANCA-Associated Vasculitis

2021 548 citations David Jayne, Thomas J. Schall et al. profile →
Chemokine receptors: Gateways to inflammation and infection

1996 547 citations Thomas J. Schall et al. profile →
Lymphotactin: a Cytokine that Represents a New Class of Chemokine

1994 546 citations Thomas J. Schall et al. profile →
RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes.

1992 535 citations Antal Rot, Thomas Brunner et al. The Journal of Experimental Medicine profile →
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

2017 420 citations David Jayne, Annette Bruchfeld et al. Journal of the American Society of Nephrology profile →

Peers

Countries citing papers authored by Thomas J. Schall

Since Specialization

Citations

This map shows the geographic impact of Thomas J. Schall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Schall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Schall more than expected).

Fields of papers citing papers by Thomas J. Schall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Schall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Schall. The network helps show where Thomas J. Schall may publish in the future.

Co-authorship network of co-authors of Thomas J. Schall

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Schall. A scholar is included among the top collaborators of Thomas J. Schall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Schall. Thomas J. Schall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evolution of Pore Volume During Stripping of Lithium Metal in Solid‐State Batteries Observed with Operando Dilatometry 2025 ·Small ·Thomas J. Schall, Till Fuchs, Janis K. Eckhardt, (unknown), Boris Mogwitz, Joachim Sann, Klaus Peppler, Jürgen Janek	0
2	Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias 2022 ·Science Advances ·(unknown), (unknown), Martin Gustavsson, S.A. Eberle, Pawel K. Dominik, Dawid Deneka, Penglie Zhang, Thomas J. Schall, Anthony A. Kossiakoff, J.J.G. Tesmer, Tracy M. Handel	43
3	CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS) 2018 ·PLoS ONE ·Zhenhua Miao, Linda Ertl, Dale Newland, Bin Zhao, Yu Wang, Xiaoping Zang, James J. Campbell, Xiaoli Liu, (unknown), Shichang Miao, (unknown), (unknown), Yibin Zeng, (unknown), Penglie Zhang, Israel Charo, Thomas J. Schall, Rajinder Singh	8
4	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis breakdown → 2017 ·Journal of the American Society of Nephrology ·David Jayne, Annette Bruchfeld, Lorraine Harper, Matthias Schaier, Michael Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimı́r Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker, (unknown)	420
5	Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis 2014 ·Nephrology Dialysis Transplantation ·David Jayne, Annette Bruchfeld, Matthias Schaier, Kazimierz Ciechanowski, Lorraine Harper, Michel Jadoul, Mårten Segelmark, Daina Selga, István Szombati, Michael Venning, (unknown), Christian Hugo, Paul Van Daele, Ondřej Viklický, Antonia Potarca, Thomas J. Schall, Pirow Bekker	4
6	CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice 2013 ·American Journal of Physiology-Renal Physiology ·Timothy J. Sullivan, Zhenhua Miao, Daniel J. Dairaghi, (unknown), Yu Wang, Bin Zhao, Trageen Baumgart, Linda Ertl, Andrew M. K. Pennell, Lisa Seitz, Jay P. Powers, Ruiping Zhao, (unknown), Zheng Wei, Landin Boring, Chia-Lin Tsou, Israel Charo, Robert Berahovich, Thomas J. Schall, Juan C. Jaén	76
7	The Chemokine Receptor CXCR7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects 2010 ·Cancer Research ·Kirsten Hattermann, Janka Held‐Feindt, Ralph Lucius, Susanne Sebens Müerköster, Mark E.T. Penfold, Thomas J. Schall, Rolf Mentlein	239
8	CXCR7 protein expression correlates with elevated mmp-3 secretion in breast cancer cells 2010 ·Oncology Letters ·Brian A. Zabel, Zhenhua Miao, (unknown), Yu Wang, Susanna Lewén, Robert Berahovich, Juan C. Jaén, Thomas J. Schall	6
9	Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease 2010 ·Journal of Pharmacology and Experimental Therapeutics ·Matthew J. Walters, Yu Wang, (unknown), Trageen Baumgart, Bin Zhao, Daniel J. Dairaghi, Pirow Bekker, Linda Ertl, Mark E.T. Penfold, Juan C. Jaén, Satish Keshav, Emily Wendt, Andrew M. K. Pennell, (unknown), Zheng Wei, John Joseph Wright, Thomas J. Schall	130
10	Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands 2009 ·The Journal of Immunology ·Brian A. Zabel, Yu Wang, Susanna Lewén, Robert Berahovich, Mark E.T. Penfold, Penglie Zhang, Jay P. Powers, (unknown), Zhenhua Miao, Bin Zhao, Ali Jalili, Anna Janowska‐Wieczorek, Juan C. Jaén, Thomas J. Schall	245
11	PROTECT-1: A Prospective Randomized Trial of CCX282-B (Traficet-EN), a Novel Oral Therapy Targeting Chemokine Receptor 9 in Crohnʼs Disease 2007 ·The American Journal of Gastroenterology ·Satish Keshav, Robert Petryka, (unknown), Yaron Niv, K Marlicz, (unknown), (unknown), Jens Frederik Dahlerup, Stefan Schreiber, Pirow Bekker, (unknown), Thomas J. Schall	1
12	Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory & clinical activity in the treatment of Crohn's disease 2007 ·Gastroenterology ·Satish Keshav, (unknown), Wei Zheng, (unknown), K Wright, Thomas J. Schall	13
13	Evidence for NK Cell Subsets Based on Chemokine Receptor Expression 2006 ·The Journal of Immunology ·Robert Berahovich, (unknown), Wei Zheng, Lewis L. Lanier, Thomas J. Schall	155
14	Expression of Human CXCR2 in Murine Neutrophils as a Model for Assessing Cytomegalovirus Chemokine vCXCL-1 Function In Vivo 2004 ·Journal of Interferon & Cytokine Research ·Tim E. Sparer, Jennifa Gosling, Thomas J. Schall, Edward S. Mocarski	15
15	Potent Immunosuppressive Activities of Cytomegalovirus- Encoded Interleukin-10 2002 ·Journal of Virology ·Juliet V. Spencer, Kristen M. Lockridge, Peter A. Barry, Gaofeng Lin, Monica Tsang, Mark E.T. Penfold, Thomas J. Schall	245
16	Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System 2000 ·The Journal of Immunology ·Ning Tong, Seth W. Perry, Qing Zhang, H. J. James, Huang Guo, Andrew I. Brooks, (unknown), (unknown), Steven M. Fine, Leon G. Epstein, Daniel J. Dairaghi, Thomas J. Schall, Howard E. Gendelman, Stephen Dewhurst, Leroy R. Sharer, Harris A. Gelbard	154
17	Glucocorticoid Inhibition of RANTES Expression in Human Lung Epithelial Cells 1995 ·American Journal of Respiratory Cell and Molecular Biology ·O Jung Kwon, P J Jose, Richard Robbins, Thomas J. Schall, Timothy J. Williams, Peter J. Barnes	104
18	Cytokine Expression by Neutrophils and Macrophages In Vivo: Endotoxin Induces Tumor Necrosis Factor-α, Macrophage Inflammatory Protein-2, Interleukin-1 β, and Interleukin-6 but not RANTES or Transforming Growth Factor-β1 mRNA Expression in Acute Lung Inflammation 1994 ·American Journal of Respiratory Cell and Molecular Biology ·Zhou Xing, Manel Jordana, Haresh Kirpalani, Kevin E. Driscoll, Thomas J. Schall, Jack Gauldie	229
19	RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. breakdown → 1992 ·The Journal of Experimental Medicine ·Antal Rot, (unknown), Thomas Brunner, Stephan C. Bischoff, Thomas J. Schall, C. A. Dahinden	535
20	The isolation and sequence of a novel gene from a human functional T cell line. 1987 ·The Journal of Experimental Medicine ·Jan Jongstra, Thomas J. Schall, B Dyer, Carol Clayberger, Jeffrey L. Jorgensen, Mark M. Davis, Alan M. Krensky	100

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact